Amadol

Quick links to important sections

Amadol

Treatment option: Pain, Chronic Pain

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amadol

Quick Facts

Property Description
Active ingredient Tramadol Hydrochloride
Form Tablets, Capsules, Oral Solution, Injection
Pharmacological class Centrally Acting Opioid Analgesic; SNRI
Common use Moderate to Moderately Severe Pain
Origin Synthetic compound

What is Amadol?

What is Amadol and What Type of Pain Medication is it?

Amadol is a prescription-only medication whose active substance is Tramadol Hydrochloride, primarily classified as a Centrally Acting Opioid Analgesic. This synthetic compound is generally used to relieve moderate to moderately severe pain, such as pain experienced after surgical procedures or due to chronic conditions. Pharmacological studies confirm that the drug's unique identity is its multimodal mechanism of action; it engages mu-opioid receptors while also acting as a weak Serotonin-Norepinephrine Reuptake Inhibitor (SNRI).

Composition, Forms, and Origin of Tramadol Hydrochloride

Although typically supplied as a single-ingredient product, the core composition involves the fully synthetic compound Tramadol, provided as the Hydrochloride salt. The active component is also available in fixed-dose combination preparations. The medication is offered in various dosage forms to match patient requirements, including immediate-release tablets and oral solution, as well as specialized prolonged-release capsules and prolonged-release tablets designed for sustained effect. A sterile solution for injection is also manufactured, allowing for parenteral administration when the oral route is impractical.

General Purpose: How Amadol Relieves Pain

Amadol’s general purpose is to provide effective, systemic relief for pain conditions that require an analgesic stronger than common non-opioid options. The mechanism of action, which involves the dual engagement of opioid receptors and monoamine reuptake inhibition, ensures a comprehensive means of altering how pain signals are transmitted and experienced. This resultant multimodal effect allows the drug to address a range of pain types by enhancing the body's natural descending pain-inhibiting pathways.

Regulatory References

  1. Tramadol Hydrochloride
  2. Centrally Acting Opioid Analgesic
  3. synthetic compound
  4. single-ingredient product

What side effects are possible with Amadol?

Possible Side Effects and Safety Information

The official safety profile for Amadol (Tramadol Hydrochloride) is defined by classifications that group documented adverse reactions by frequency and the body system affected. These classifications distinguish between frequently reported, non-serious effects and rare but clinically significant reactions, as established in government regulatory labeling.

Frequency-Classified Adverse Reactions

Adverse reactions are classified according to regulatory frequency standards. Very Common side effects (ge 1 in 10 patients) include nausea and dizziness/vertigo. Common effects (1 in 10 to 1 in 100) encompass headache, somnolence, vomiting, constipation, dry mouth, and sweating. Less frequent effects classified as Rare or Uncommon involve cardiovascular changes like tachycardia or hypotension, as well as skin reactions like pruritus and rash. Serious reactions such as Serotonin Syndrome and Hypoglycemia have been reported with a Not Known frequency, meaning it cannot be reliably estimated from available data.

Serious Adverse Reactions and Safety Constraints

The prescribing information explicitly documents several serious adverse reactions. These include Respiratory Depression (potentially life-threatening, especially upon treatment initiation or dose increase), Serotonin Syndrome, and the risk of Convulsions (seizures). Prolonged use carries the risk of Opioid Dependence and tolerance.

Safety constraints exist for specific populations; the medication is contraindicated in children younger than 12 years and is not recommended for individuals identified as CYP2D6 ultra-rapid metabolizers, who face an elevated risk of respiratory depression. Additionally, caution and dose adjustments are required for older adults and patients with severe renal or hepatic impairment.

Overdose and Emergency Response

Overdose and When to Seek Emergency Help

Amadol (Tramadol Hydrochloride) is an opioid medicine, and its use carries a risk of serious or fatal overdose, which is significantly increased with higher doses or when combined with other central nervous system (CNS) depressants like alcohol or benzodiazepines. Accidental ingestion, particularly by a child, can result in a fatal overdose and requires immediate emergency intervention.

Signs of an overdose typically involve severe respiratory and neurological impairment. Symptoms may include:

Physiological System Documented Manifestations
Respiratory Severe, shallow, or stopped breathing; long pauses between breaths.
Central Nervous System Profound sedation, extreme sleepiness, inability to wake up or respond (coma), and seizures.
Other Pinpoint pupils (miosis), weak pulse, muscle weakness, and cold, clammy skin.

Immediate Medical Attention Required

If you or someone else experiences any of the severe signs listed above—especially slowed or absent breathing, loss of consciousness, or a seizure—call emergency medical services immediately. Overdose management prioritizes establishing a clear airway and supporting ventilation. Naloxone, an opioid antagonist, can be administered to temporarily reverse respiratory depression but its use is complex due to the potential to trigger or worsen seizures. Continuous medical monitoring is necessary following any suspected overdose.

Therapeutic Uses of Amadol

What Amadol treats: Main Uses and Benefits

Amadol (Tramadol Hydrochloride) is generally used to help manage moderate to moderately severe symptoms related to physical discomfort, which may be part of symptomatic management. It is commonly used in clinical settings where additional management of discomfort is required.

The medication is relevant in conditions characterized by periods of heightened symptoms, including those where supportive symptom management is appropriate. It is applied across domains where additional symptomatic support is needed, such as in addressing symptoms associated with surgical procedures or physical trauma, and in managing persistent pain syndromes linked to chronic conditions. It supports patients during difficult episodes by easing distress and may assist with maintaining functional stability when symptoms are more noticeable.

“It assists with managing symptoms that interfere with daily functioning, supporting patients during episodes of heightened discomfort.”


Quick Fact: Easing Persistent Discomfort
Primary Focus Moderate to moderately severe pain symptoms.
Usage Context Acute post-surgical phases and chronic ongoing conditions.
Patient Benefit Contributes to easing the overall symptom load and may assist with maintaining functional stability.

Eligibility and Restrictions for Use

Who can and cannot use Amadol?

Amadol (Tramadol Hydrochloride) eligibility is strictly defined by government regulatory labeling, establishing clear rules for authorized and prohibited populations.

Absolute Contraindications (Must Not Use)

Use of Amadol is contraindicated (absolutely prohibited) in several populations. This includes patients with known hypersensitivity to tramadol or any opioid, and individuals experiencing acute intoxication from central nervous system depressants. Patients who are currently taking or have recently discontinued Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days must not use the medicine. It is also contraindicated for patients whose epilepsy is not adequately controlled by treatment, and in the presence of severe respiratory depression.

Age-Related and Organ Function Restrictions

Population Group Regulatory Status
Children under 12 years Not recommended for pain relief.
Adolescents under 18 Contraindicated for specific post-operative pain management (e.g., after tonsillectomy).
Older Adults (over 75) Use with caution; requires special consideration.
Severe Hepatic/Renal Impairment Use is generally not recommended.

Pregnancy and Lactation

Use is not recommended during pregnancy, particularly in the third trimester, and is not recommended while breastfeeding. The label also specifies restrictions for patients with a history of seizure disorders or substance dependence, where use must be with caution.

What should I know about interactions with other medicines?

The regulatory interaction profile for Amadol (Tramadol Hydrochloride) includes several mandatory restrictions for co-administration. Use with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated, and a separation period of 14 days is required before or after initiating treatment. Combining Amadol with other tramadol-containing products is also strictly prohibited.

Significant pharmacodynamic interactions are documented with substances affecting the central nervous system (CNS). Co-administration with CNS depressants (including alcohol, benzodiazepines, and other opioids) carries an official risk of profound sedation and severe respiratory depression. Due to its effect on monoamines, simultaneous use with other serotonergic drugs (such as SSRIs and SNRIs) is associated with an officially increased risk of Serotonin Syndrome.

The profile also details pharmacokinetic constraints related to liver enzyme metabolism. Substances that inhibit the CYP2D6 or CYP3A4 enzymes may increase the plasma concentration of Amadol. Conversely, CYP3A4 inducers, such as Carbamazepine, may increase metabolism, leading to a reduced analgesic effect. The interaction profile further notes that use with Warfarin is officially linked to an increased risk of bleeding due to reports of an elevated International Normalised Ratio (INR). The regulatory documents advise that individuals known to be CYP2D6 ultra-rapid metabolizers should not use this product.

Mechanism of Action

Modulates Key Receptor-Mediated Signaling

Amadol exerts its pharmacodynamic effect through specific interactions at the molecular level. The drug acts within domains involving receptor-mediated signaling to modulate systems where specific transmitters or mediators dominate. This interaction alters the conformational state of the target receptors, initiating or suppressing signaling sequences that ultimately contribute to modifying the activity profile of the relevant physiological systems.


Adjusts Core Enzyme and Pathway Activity

Furthermore, Amadol engages regulatory mechanisms associated with heightened signaling flux by modulating key pathways and associated physiological responses. It modifies early molecular steps within intracellular processes, leading to a reduction in the magnitude of mediator activity.


Influences Feedback Regulation Within Cascades

The cumulative effect is a modulation of processes driven by distinct signaling patterns, influencing feedback regulation within cascades and resulting in specific physiological adjustments at the system level.

Dosage and Administration Information

How to Use Amadol: Official Administration Guidelines

The administration of Amadol (Tramadol Hydrochloride) is governed by protocols concerning the route, frequency, and dose limits. The medicine is authorized for oral use, available as immediate-release (IR) tablets, extended-release (ER) capsules, and solution, and for parenteral use via intravenous (IV), intramuscular (IM), or subcutaneous (SC) injection.

Dosing is dependent on the formulation used. Immediate-release oral forms are typically administered at 50 mg to 100 mg per dose, taken every four to six hours as needed, with a maximum limit of 400 mg per day for most adult regimens. In contrast, the extended-release forms are administered once daily, with a maximum daily dose generally restricted to 300 mg.

Specific handling rules must be followed for correct use. Extended-release tablets and capsules must be swallowed whole and must not be crushed, split, or chewed to avoid rapid release of the active substance. While IR forms may be taken without regard to meals, ER forms must be taken consistently (either always with or always without food).

Guidelines emphasize that treatment should be for the shortest possible duration. Dose modifications are required for specific patient populations, including patients over 75 years of age and those with severe renal or hepatic impairment, often requiring an extension of the dosing interval and a reduced maximum daily dose. Discontinuation of Amadol requires a gradual reduction (tapering) of the dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Amadol

This section summarizes the types of studies that have examined Amadol (Tramadol Hydrochloride), detailing what researchers have measured and where the current evidence remains limited or uncertain. This information is purely descriptive of the research and should not be used for self-assessment or to make treatment decisions.


Evidence for Use in Acute Pain Management

Research has explored how Amadol was studied in relation to symptom change over time following acute events, such as physical discomfort that occurs immediately following surgical procedures or physical trauma. The primary research design used in this area is the Randomized Controlled Trial (RCT), which allows researchers to monitor and document symptoms in patients who receive the study drug versus a comparison substance or standard care.

In these studies, researchers monitored patient-reported outcomes describing perceived discomfort and tracked the need for supplemental pain relief medication (rescue analgesia). The evidence describing these short-term research patterns is generally assigned a moderate certainty rating, contributing to the overall research available for acute symptom management.


Evidence for Use in Persistent Pain Syndromes (Chronic Pain)

The research base exploring Amadol in conditions characterized by fluctuating or episodic manifestations, such as pain associated with osteoarthritis or fibromyalgia, is primarily built on systematic reviews and meta-analyses of RCTs. These studies evaluated the drug's role in conditions where symptoms may vary in intensity over a longer time frame.

Research examined outcomes related to physical discomfort (mean pain scores) and, in some cases, outcomes reflecting daily functioning or activity level. Findings across the studies were mixed; while some trials reported measurements of pain score changes, the magnitude of the change measured was sometimes noted as being below the level considered meaningful for most patients in daily life. This evidence base for chronic conditions is broadly assigned a low certainty rating in systematic assessments.


Research Gaps: What is Still Uncertain about Amadol

Key areas of uncertainty in the research landscape include the limited duration of available studies. Follow-up durations were limited, typically not extending beyond 4 months in key comparative studies. This means that long-term effects are not fully established regarding how outcomes related to physical discomfort or daily functioning are documented after many months or years of observation. Additionally, for chronic pain, research describes that evidence quality varies across studies, with some systematic reviews indicating that underlying trials had limitations like sample sizes were modest or a high risk of bias.

Frequently Asked Questions (FAQ)

Common questions about Amadol (FAQ)


Q: How quickly does Amadol typically start working?

A: Official product information indicates that the onset of action for the immediate-release form is described as occurring approximately within one hour of dosing. This is based on measurements of the drug's activity in the body as described in regulatory documents.


Q: How long does the effect of Amadol usually last?

A: The typical duration of the pain-relieving effect for a single dose of the immediate-release form of Amadol is approximately six hours. This timeframe aligns with the drug's half-life and guides its prescribed frequency.


Q: Is a slight headache a normal side effect when starting Amadol?

A: According to the official safety profile, headache is classified as a Common side effect. This means it has been reported to affect between 1 in 10 and 1 in 100 people using the medication.


Q: Does Amadol cause drowsiness or affect alertness?

A: Yes, official safety information lists both drowsiness (somnolence) and dizziness/vertigo as frequently reported side effects. These effects are classified as very common or common in the official safety profile.


Q: Can Amadol be used by teenagers?

A: Regulatory labeling restricts the use of Amadol based on age. It is contraindicated for children under 12 years old. Furthermore, it is generally not recommended for adolescents under 18 years old who are recovering from specific surgical procedures, such as a tonsillectomy or adenoidectomy.


Q: Is it necessary to stop taking Amadol gradually?

A: Regulatory documents recommend that the dose be gradually reduced (tapering) when stopping the medicine. This gradual reduction process is intended to help the body adjust and may lessen the experience of withdrawal symptoms.


Q: Are there any known issues with stopping Amadol suddenly?

A: Yes, official safety warnings indicate that sudden discontinuation may lead to withdrawal symptoms. These symptoms can include physical discomfort, shaking, sweating, anxiety, or panic attacks.


Q: Is Amadol safe to use before driving or operating machinery? (Informational only)

A: Official warnings state that the drug can cause dizziness and somnolence. Due to these potential effects, official warnings advise caution regarding driving or operating machinery until the user knows how the medicine affects their alertness.


Q: How is the long-term safety of Amadol described in official documents?

A: Official documents note that prolonged use carries the risks of developing physical dependence and tolerance. Tolerance means the body may need a higher dose over time to achieve the same effect.


Q: Why do some people need to adjust their use of Amadol over time?

A: The need for adjustment is primarily linked to the possibility of developing tolerance over time. This change may result in the original dose becoming less effective. In rare instances, adjustments may be considered due to increased pain sensitivity, which official documents refer to as hyperalgesia.


Q: How long do most patients stay on Amadol?

A: Official regulatory guidance advises that treatment with Amadol should be for the shortest possible duration. For certain formulations or uses, short-term management is specifically outlined in regulatory indications.


Q: Is Amadol used for long-term conditions?

A: Yes, the extended-release forms of Amadol are approved for use in the management of moderate to moderately severe chronic pain. This applies to pain that requires continuous, around-the-clock medication for an extended period.


Q: Is Amadol the same type of medicine as [Common similar drug]? (No superiority claims)

A: Amadol is officially classified as a Centrally Acting Opioid Analgesic with a unique dual mechanism of action. This pharmacological classification places it in a different category from common non-opioid medications.


Q: Are there any common foods that interact with Amadol?

A: Official regulatory documents state that the absorption of the immediate-release formulation of Amadol is not significantly affected by co-administration with food. No specific food interactions are noted in the safety profile.


Q: Do you have to take Amadol with a meal?

A: The immediate-release form can generally be taken with or without food. However, the extended-release forms should be taken consistently—always with food or always without—at the same time each day to maintain steady absorption.


Q: What are the most commonly reported side effects of Amadol?

A: The official safety profile reports that the most frequent side effects, classified as Very Common (affecting ge 1 in 10 patients), include nausea and dizziness/vertigo.


Q: Is Amadol considered an opioid or a controlled substance?

A: Amadol is classified as a Centrally Acting Opioid Analgesic. In the United States, it is also classified as a Schedule IV controlled substance, which is a designation used by the government to track medicines with a potential for misuse.


Q: Can Amadol affect sleep patterns?

A: Official information lists somnolence (drowsiness) as a possible side effect. Additionally, difficulty sleeping (insomnia) can be experienced as a symptom if the medicine is stopped suddenly without the recommended tapering process.


Q: Are there common misconceptions about how Amadol works?

A: Regulatory information highlights the fact that Amadol has a multimodal mechanism of action—it acts on opioid receptors and also affects monoamine levels. This dual action described in the regulatory literature serves as the basis for its therapeutic effect.


Q: Why is Amadol not available over the counter in most places?

A: Amadol is only available by prescription because it is classified by regulatory agencies as a Schedule IV controlled substance. This classification is assigned due to the medicine's potential for misuse, physical dependence, and addiction.


Q: Does Amadol cause stomach upset for many people?

A: The official safety profile documents that gastrointestinal side effects such as nausea and vomiting are classified as Very Common or Common. These are among the most frequently reported potential effects.


Q: Is it normal to feel a change in appetite while using Amadol?

A: Yes, regulatory safety documents include loss of appetite (anorexia) among the documented gastrointestinal disorders. This is listed as one of the potential effects of the medicine.


Q: Does Amadol affect blood sugar levels?

A: Cases of hypoglycemia (abnormally low blood sugar) have been reported as a serious adverse reaction associated with the use of this medicine, according to official adverse event reporting systems.


Q: What happens if I miss a scheduled time to use Amadol?

A: Official instructions advise users to take the next dose exactly as prescribed. Warnings caution against taking an increased amount in a single dose or taking more doses per day than authorized.


Q: Is Amadol a new drug, or has it been around for a while?

A: The active ingredient in Amadol was first synthesized in 1962 and began being marketed in Germany in 1977. It received initial regulatory approval in the United States in 1995, indicating it has been available for several decades.


Q: How is the effect of Amadol measured in clinical studies?

A: In clinical studies, researchers commonly measure outcomes related to patient-reported outcomes describing perceived discomfort and mean pain scores. They also track outcomes reflecting changes in daily functioning or activity levels.


Q: Does the time of day matter when taking Amadol?

A: The time of day is important for the extended-release form, which should be taken at about the same time every day to maintain steady drug levels. The immediate-release form is usually taken as needed.

How should Amadol be stored and disposed of?

How to Store and Dispose of Amadol (Tramadol Hydrochloride)

Official regulatory guidelines mandate specific conditions for the storage and disposal of Amadol to maintain product stability and ensure public safety.

Storage Requirements

Amadol must be stored at Controlled Room Temperature, specifically defined as 20 mathrmC to 25 mathrmC (68 mathrmF to 77 mathrmF). It is essential to protect the medicine from moisture, excessive heat, and light, and it must not be frozen. The product should be kept in its original, tightly closed container.

As a mandatory safety requirement, Amadol must be stored in a secure location, strictly out of the sight and reach of children and pets.

Disposal Instructions

To prevent misuse, unused or expired Amadol should be discarded as soon as it is no longer needed. The preferred method is using a formal drug take-back program. If a take-back option is unavailable, regulatory guidance for this specific opioid recommends immediately flushing the unused medicine down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amadol found in:

A-Z Index: